Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome.

Sun B, Lu Y, Liu W, Wang C.

Open source

DOI
10.1371/journal.pone.0349155
Published
2026-08-26
Container
PLoS One
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0349155,
  title = {Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome.},
  author = {Sun B and  Lu Y and  Liu W and  Wang C.},
  year = {2026},
  journal = {PLoS One},
  doi = {10.1371/journal.pone.0349155},
  url = {https://doi.org/10.1371/journal.pone.0349155}
}

RIS

TY  - JOUR
TI  - Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome.
AU  - Sun B
AU  -  Lu Y
AU  -  Liu W
AU  -  Wang C.
PY  - 2026
JO  - PLoS One
DO  - 10.1371/journal.pone.0349155
UR  - https://doi.org/10.1371/journal.pone.0349155
ER  - 

APA

B, S., Y, L., W, L., & C., W. (2026). Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome.. PLoS One. https://doi.org/10.1371/journal.pone.0349155

Source records